Target Name: OGFRL1
NCBI ID: G79627
Review Report on OGFRL1 Target / Biomarker Content of Review Report on OGFRL1 Target / Biomarker
OGFRL1
Other Name(s): Opioid growth factor receptor-like protein 1 (isoform b) | dJ331H24.1 | Opioid growth factor receptor like 1, transcript variant 2 | opioid growth factor receptor like 1 | OGRL1_HUMAN | OGFRL1 variant 2 | Opioid growth factor receptor-like protein 1

OGFRL1: A Potential Drug Target and Biomarker forOpioid Overuse and Addiction

Opioid overuse and addiction have become a significant public health issue worldwide, leading to significant morbidity and mortality. The opioid system is a complex neurotransmitter system that plays a crucial role in pain modulation and mood regulation. However, abuse of opioids can lead to addiction, leading to a vicious cycle that increases the risk of overdose and mortality. The OGFRL1 gene, which encodes a protein called OGFRL1 (Opioid Growth Factor Receptor-Like Protein 1), has been identified as a potential drug target and biomarker for the treatment of opioid overuse and addiction.

OGFRL1 Structure and Function

OGFRL1 is a 25 kDa transmembrane protein that belongs to the G protein-coupled receptor (GPCR) family. GPCR is a large family of membrane receptors that play a crucial role in cellular signaling. The OGFRL1 gene is located on chromosome X and encodes a protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain.

The OGFRL1 protein is characterized by a long N-terminal cytoplasmic region, a short transmembrane region, and a long C-terminal intracellular region. The cytoplasmic region contains a putative GPCR-like extracellular domain that is involved in cell adhesion and interaction with other proteins. The transmembrane region contains a putative transmembrane domain that is involved in protein-protein interaction and intracellular signaling. The intracellular region contains a putative intracellular domain that is involved in protein-protein interaction and intracellular signaling.

Functional assays have shown that OGFRL1 is involved in various cellular signaling pathways, including cell adhesion, migration, and survival. OGFRL1 has been shown to play a role in the regulation of pain perception and addiction. For example, OGFRL1 has been shown to regulate the release of endogenous opioids, such as endorphins, and to modulate the activity of pain modulatory neurons. In addition, OGFRL1 has been shown to play a role in the regulation of dopamine release and metabolism, which is involved in the modulation of mood and behavior.

Drug Interaction with OGFRL1

Several drugs have been shown to interact with OGFRL1 and to modulate its function. For example, selective OGFRL1 antagonists have been shown to be effective in reducing the abuse of opioids and in treating opioid addiction. Additionally, OGFRL1 inhibitors have been shown to be effective in reducing the release of endogenous opioids and in modulating the activity of pain modulatory neurons.

Biomarker Properties

OGFRL1 has been shown to be a potential biomarker for the diagnosis of opioid overuse and addiction. OGFRL1 levels have been shown to be elevated in individuals with opioid addiction and to decrease in individuals with opioid overuse. In addition, OGFRL1 has been shown to be involved in the regulation of pain perception and has been used as a marker for the efficacy of opioid treatment.

Conclusion

OGFRL1 is a protein that has been shown to play a role in the regulation of various cellular processes, including pain perception and addiction. The potential drug target and biomarker properties of OGFRL1 make it an attractive target for the development of new treatments for opioid overuse and addiction. Further research is needed to fully understand the role of OGFRL1 in pain modulation and addiction and to develop effective treatments.

Protein Name: Opioid Growth Factor Receptor Like 1

The "OGFRL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OGFRL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OGFRP1 | OGG1 | OGN | OGT | OIP5 | OIP5-AS1 | OIT3 | OLA1 | OLA1P1 | OLAH | OLFM1 | OLFM2 | OLFM3 | OLFM4 | OLFML1 | OLFML2A | OLFML2B | OLFML3 | OLIG1 | OLIG2 | OLIG3 | Oligosaccharyltransferase complex | OLMALINC | OLR1 | OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1